Search Results

Edwards Lifesciences announced it has entered into a definitive agreement to sell its Critical Care product group to BD, in an all-cash transaction valued at $4.2 billion.

Edwards Lifesciences reported financial results for the quarter ended March 31, 2024.

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Edwards Lifesciences reported financial results for the quarter ended December 31, 2023.

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024.

BD, a leading global medical technology company, and Edwards Lifesciences, announced a definitive agreement under which BD will acquire Edwards’ Critical Care product group, a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD’s portfolio of smart connected care solutions.

Edwards Lifesciences announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement patients with a small annulus.

Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference.

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Edwards Lifesciences reported financial results for the quarter ended Sept. 30, 2023.